Research Reports Initiation on Biotech Stocks -- Agenus, Nektar Therapeutics, GlobeImmune and Anthera Pharma

NEW YORK, September 20, 2016 /PRNewswire/ --

Ahead of today's trading session, reviews the most recent performances of Agenus Inc. (NASDAQ: AGEN), Nektar Therapeutics (NASDAQ: NKTR), GlobeImmune Inc. (NASDAQ: GBIM), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). These companies belong to the Biotech industry, which is slowly gaining strength but remains down -17% YTD. Learn more about these stocks by downloading their free report at:


Lexington, Massachusetts headquartered Agenus Inc.'s stock finished Monday's session flat at $6.77. A total volume of 1.53 million shares was traded, which was above their three months average volume of 1.10 million shares. The Company's shares have advanced 13.40% in the past month, 60.43% over the previous three months, and 49.12% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 18.33% and 57.18%, respectively. Furthermore, shares of Agenus, which focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 65.54. The free research report on AGEN is available at:

Nektar Therapeutics  

On Monday, shares in San Francisco, California headquartered Nektar Therapeutics ended the session at $18.99, down 0.47%. The stock recorded a trading volume of 909,805 shares. The Company's shares have gained 7.17% in the last one month, 24.85% over the previous three months, and 12.70% since the start of this year. The stock is trading 10.53% above its 50-day moving average and 27.03% above its 200-day moving average. Moreover, shares of Nektar Therapeutics, which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 59.23.

On August 3rd, 2016, Nektar Therapeutics reported that revenue in Q2 2016 was $32.8 million as compared to $22.7 million in Q2 2015. The company's net loss in Q2 2016 was $48.6 million, or $0.36 loss per share, as compared to $52.7 million, or $0.40 loss per share, in Q2 2015. Cash and investments in marketable securities at June 30th, 2016 were $274.9 million as compared to $308.9 million at December 31st, 2015. This balance includes the $28.0 million payment received from AstraZeneca in April of 2016 for the sublicense of MOVENTIG® (naloxegol) to ProStraken in Europe. The complimentary report on NKTR can be downloaded at:


Louisville, Colorado headquartered GlobeImmune Inc.'s stock ended yesterday's session 1.78% higher at $0.77 and with a total trading volume of 14,175 shares. Shares of the Company, which focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform, are trading 5.13% below their 50-day moving average. The stock has an RSI of 45.90. Visit us today and download our complete research report on GBIM for free at:

Anthera Pharma  

At the close on Monday, shares in Hayward, California headquartered Anthera Pharmaceuticals Inc. recorded a trading volume of 614,891 shares, which was above their three months average volume of 503,220 shares. The stock finished 3.27% lower at $2.96. The Company's shares are trading below their 50-day moving average by 6.06%. Furthermore, shares of Anthera Pharmaceuticals, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have an RSI of 44.87.

On September 8th, 2016, Anthera Pharmaceuticals announced that it has agreed to sell preferred convertible stock in two tranches to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P., and Rock Springs Capital for initial proceeds of $17.0 million with an option for an additional $28.33 million to be invested at the option of the investors. Each share of preferred stock is convertible into shares of common stock at various prices in the future with the initial $17.0 million of preferred stock receiving warrant coverage equal to 25% of the issued shares of common stock with an exercise price equal to 120% of the conversion price. Get free access to your technical report on ANTH at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.